European Medicines Agency validates Bristol Myers Squibb’s application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)
MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B Application based on positive results from TRANSCEND NHL 001 study and additional TRANSCEND WORLD 001 study PRINCETON, N.J.–(BUSINESS